12:00 AM
 | 
Nov 17, 2008
 |  BC Week In Review  |  Clinical News  |  Regulatory

Y-90 epratuzumab regulatory update

FDA granted Orphan Drug designation to Immunomedics for epratuzumab to treat acute lymphoblastic leukemia...

Read the full 47 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >